CY1119914T1 - Νεο αντι-ανθρωπινο ngf αντισωμα - Google Patents
Νεο αντι-ανθρωπινο ngf αντισωμαInfo
- Publication number
- CY1119914T1 CY1119914T1 CY20181100180T CY181100180T CY1119914T1 CY 1119914 T1 CY1119914 T1 CY 1119914T1 CY 20181100180 T CY20181100180 T CY 20181100180T CY 181100180 T CY181100180 T CY 181100180T CY 1119914 T1 CY1119914 T1 CY 1119914T1
- Authority
- CY
- Cyprus
- Prior art keywords
- human ngf
- ngf antibody
- antibody
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Να παρέχεται αντι-ανθρώπινου NGF αντίσωμα ή θραύσμα σύνδεσης αντιγόνου αυτού που είναι εξαιρετικό στην ασφάλεια με μείωση του κινδύνου παρενεργειών όπως αποτελεσμάτων επί εμβρύου και σχηματισμού θρόμβου, ενώ διατηρεί εντόνως εξουδετερωτική δραστικότητα και να παρέχονται μέσα για αποτροπή ή θεραπεία διαφόρων ασθενειών στις οποίες ενέχεται ανθρώπινος NGF στη δημιουργία παθολογικών καταστάσεων, με χρήση του αντισώματος ή του θραύσματος σύνδεσης αντιγόνου αυτού. [Μέσα για Επίλυση] Ένα αντι-ανθρώπινου NGF αντισώματος Fab' θραύσμα που περιλαμβάνει μεταβλητή περιοχή βαριάς αλύσου που συνίσταται από αλληλουχία αμινοξέος που δείχνεται από τη SEQ ID ΝΟ:6 κα μεταβλητή περιοχή ελαφρός αλύσου που συνίσταται από αλληλουχία αμινοξέος π. δείχνεται με SEQ ID ΝΟ:4.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011176209 | 2011-08-11 | ||
JP2011269215 | 2011-12-08 | ||
PCT/JP2012/070433 WO2013022083A1 (ja) | 2011-08-11 | 2012-08-10 | 新規抗ヒトngf抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119914T1 true CY1119914T1 (el) | 2018-06-27 |
Family
ID=47668585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100180T CY1119914T1 (el) | 2011-08-11 | 2018-02-14 | Νεο αντι-ανθρωπινο ngf αντισωμα |
Country Status (28)
Country | Link |
---|---|
US (2) | US8986952B2 (el) |
EP (1) | EP2743348B1 (el) |
JP (1) | JP5376095B2 (el) |
KR (1) | KR101999867B1 (el) |
CN (1) | CN103748222B (el) |
AR (1) | AR087506A1 (el) |
AU (1) | AU2012293161B2 (el) |
BR (1) | BR112014002576B1 (el) |
CA (1) | CA2841181C (el) |
CY (1) | CY1119914T1 (el) |
DK (1) | DK2743348T3 (el) |
EA (1) | EA024292B1 (el) |
ES (1) | ES2663968T3 (el) |
HR (1) | HRP20180155T1 (el) |
HU (1) | HUE036079T2 (el) |
IL (1) | IL230797A (el) |
IN (1) | IN2014CN00614A (el) |
LT (1) | LT2743348T (el) |
ME (1) | ME02944B (el) |
MX (1) | MX351273B (el) |
NO (1) | NO2743348T3 (el) |
PL (1) | PL2743348T3 (el) |
PT (1) | PT2743348T (el) |
RS (1) | RS56876B1 (el) |
SI (1) | SI2743348T1 (el) |
TW (1) | TWI554519B (el) |
WO (1) | WO2013022083A1 (el) |
ZA (1) | ZA201400741B (el) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
JP6190723B2 (ja) | 2010-12-01 | 2017-08-30 | アルダーバイオ ホールディングス エルエルシー | 抗ngf組成物およびその使用 |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
JP6135161B2 (ja) * | 2013-02-08 | 2017-05-31 | アステラス製薬株式会社 | 新規抗ヒトngf抗体 |
US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
CN107614683B (zh) * | 2015-05-22 | 2020-12-22 | 安斯泰来制药株式会社 | 新型抗人NGF抗体Fab片段 |
TW201738269A (zh) * | 2016-03-25 | 2017-11-01 | 安斯泰來製藥股份有限公司 | 含有PEG化抗人類NGF抗體Fab’片段之醫藥組成物 |
CN109929035B (zh) * | 2017-12-15 | 2022-06-28 | 安源医药科技(上海)有限公司 | 抗人ngf抗体及其制备方法和用途 |
EP3795176A4 (en) | 2018-05-15 | 2022-01-12 | Astellas Pharma Inc. | PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF ATRIAL FIBRILLATION WITH ANTI-HUMAN NGF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AS AN ACTIVE SUBSTANCE |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
KR100337069B1 (ko) * | 1993-03-11 | 2002-10-11 | 사이단호진가가쿠오요비겟세이리요호오겐큐쇼 | 항-hiv모노클로날항체 |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CA2448956C (en) | 2001-05-30 | 2017-10-03 | Genentech, Inc. | Anti-ngf antibodies for the treatment of various disorders |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
NZ540730A (en) | 2002-12-24 | 2010-09-30 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
NZ599196A (en) | 2003-07-15 | 2014-01-31 | Amgen Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
KR101298383B1 (ko) | 2005-01-24 | 2013-08-20 | 엘란 파마 인터내셔널 리미티드 | Ngf에 대한 특이적 결합 멤버 |
PT2187964E (pt) | 2007-08-10 | 2015-01-14 | Regeneron Pharma | Anticorpos humanos de elevada afinidade para o factor de crescimento neural humano |
US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
RU2461551C2 (ru) | 2007-10-24 | 2012-09-20 | Астеллас Фарма Инк. | Азолкарбоксамидное соединение или его фармацевтически приемлемая соль |
PT2448970E (pt) | 2009-05-04 | 2014-10-20 | Abbvie Res B V | Anticorpos contra factor de crescimento nervoso (ngf) com estabilidade in vivo melhorada |
-
2012
- 2012-08-10 US US13/879,267 patent/US8986952B2/en active Active
- 2012-08-10 CA CA2841181A patent/CA2841181C/en active Active
- 2012-08-10 IN IN614CHN2014 patent/IN2014CN00614A/en unknown
- 2012-08-10 AU AU2012293161A patent/AU2012293161B2/en not_active Ceased
- 2012-08-10 LT LTEP12821758.5T patent/LT2743348T/lt unknown
- 2012-08-10 JP JP2013525474A patent/JP5376095B2/ja active Active
- 2012-08-10 ES ES12821758.5T patent/ES2663968T3/es active Active
- 2012-08-10 TW TW101128963A patent/TWI554519B/zh active
- 2012-08-10 RS RS20180173A patent/RS56876B1/sr unknown
- 2012-08-10 HU HUE12821758A patent/HUE036079T2/hu unknown
- 2012-08-10 PL PL12821758T patent/PL2743348T3/pl unknown
- 2012-08-10 SI SI201231222T patent/SI2743348T1/en unknown
- 2012-08-10 DK DK12821758.5T patent/DK2743348T3/en active
- 2012-08-10 PT PT128217585T patent/PT2743348T/pt unknown
- 2012-08-10 CN CN201280039293.3A patent/CN103748222B/zh active Active
- 2012-08-10 ME MEP-2018-28A patent/ME02944B/me unknown
- 2012-08-10 KR KR1020147003155A patent/KR101999867B1/ko active IP Right Grant
- 2012-08-10 AR ARP120102927 patent/AR087506A1/es active IP Right Grant
- 2012-08-10 MX MX2014001627A patent/MX351273B/es active IP Right Grant
- 2012-08-10 EP EP12821758.5A patent/EP2743348B1/en active Active
- 2012-08-10 BR BR112014002576-2A patent/BR112014002576B1/pt active IP Right Grant
- 2012-08-10 WO PCT/JP2012/070433 patent/WO2013022083A1/ja active Application Filing
- 2012-08-10 EA EA201490433A patent/EA024292B1/ru not_active IP Right Cessation
- 2012-08-10 NO NO12821758A patent/NO2743348T3/no unknown
-
2014
- 2014-01-30 ZA ZA2014/00741A patent/ZA201400741B/en unknown
- 2014-02-03 IL IL230797A patent/IL230797A/en active IP Right Grant
-
2015
- 2015-01-14 US US14/596,874 patent/US20150218265A1/en not_active Abandoned
-
2018
- 2018-01-26 HR HRP20180155TT patent/HRP20180155T1/hr unknown
- 2018-02-14 CY CY20181100180T patent/CY1119914T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119914T1 (el) | Νεο αντι-ανθρωπινο ngf αντισωμα | |
CY1119445T1 (el) | Αντισωματα εναντι του ανθρωπινου gdf8 | |
CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
CY1124435T1 (el) | Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α | |
NZ706377A (en) | Il-6 antagonists and uses thereof | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
CY1119994T1 (el) | Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α | |
MX2021008888A (es) | Anticuerpos anti-tau humanizados. | |
PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
HRP20231514T1 (hr) | Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka | |
NZ594682A (en) | Fully human antibodies specific to cadm1 | |
UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
NZ626269A (en) | Anti-phf-tau antibodies and their uses | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
EA201070888A1 (ru) | Антитела и их производные | |
NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
NZ586053A (en) | Anti-vegf antibody compositions and methods | |
BR112012021327B8 (pt) | anticorpo monoclonal anti-her2 humanizado, método de preparação e uso do mesmo. | |
EA201591191A1 (ru) | Антитела против ntb-a и связанные с ними композиции и способы | |
EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
BR112015027587A2 (pt) | Anticorpos anti-vegf e uso dos mesmos | |
EA201492163A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ | |
AR098663A1 (es) | Anticuerpos multifuncionales que se unen a egfr y met | |
PH12017500094A1 (en) | Novel anti-human tie-2 antibody |